All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 43 points (-0.2%) at 17,678 as of Wednesday, Dec. 30, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,064 issues advancing vs. 1,854 declining with 167 unchanged.

The Drugs industry currently sits down 0.5% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include

Opko Health

(

OPK

), down 3.4%,

Incyte

(

INCY

), down 1.4% and

Sanofi

(

SNY

), down 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Illumina

(

ILMN

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Illumina is down $2.89 (-1.5%) to $191.29 on light volume. Thus far, 310,681 shares of Illumina exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $190.73-$196.47 after having opened the day at $195.13 as compared to the previous trading day's close of $194.18.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $27.5 billion and is part of the health care sector. Shares are up 5.2% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates

Illumina

as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full

Illumina Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Amgen

(

AMGN

) is down $0.90 (-0.6%) to $163.54 on light volume. Thus far, 419,887 shares of Amgen exchanged hands as compared to its average daily volume of 3.5 million shares. The stock has ranged in price between $162.91-$164.75 after having opened the day at $164.61 as compared to the previous trading day's close of $164.44.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. Amgen has a market cap of $122.0 billion and is part of the health care sector. Shares are up 3.2% year-to-date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Amgen a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates

Amgen

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, reasonable valuation levels and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Amgen Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Gilead

(

GILD

) is down $1.16 (-1.1%) to $102.20 on light volume. Thus far, 1.8 million shares of Gilead exchanged hands as compared to its average daily volume of 9.5 million shares. The stock has ranged in price between $102.03-$103.05 after having opened the day at $102.84 as compared to the previous trading day's close of $103.36.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $146.5 billion and is part of the health care sector. Shares are up 9.7% year-to-date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Gilead a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Gilead

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and good cash flow from operations. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Gilead Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).